Premium
Novel prognostic protein markers of resectable pancreatic cancer identified by coupled shotgun and targeted proteomics using formalin‐fixed paraffin‐embedded tissues
Author(s) -
Takadate Tatsuyuki,
Onogawa Tohru,
Fukuda Tetsuya,
Motoi Fuyuhiko,
Suzuki Takashi,
Fujii Kiyonaga,
Kihara Makoto,
Mikami Sayaka,
Bando Yasuhiko,
Maeda Shimpei,
Ishida Kazuyuki,
Minowa Takashi,
Hanagata Nobutaka,
Ohtsuka Hideo,
Katayose Yu,
Egawa Shinichi,
Nishimura Toshihide,
Unno Michiaki
Publication year - 2012
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.27797
Subject(s) - shotgun proteomics , shotgun , pancreatic cancer , proteomics , cancer , medicine , pathology , cancer research , oncology , biology , gene , biochemistry
Pancreatic cancer is among the most lethal malignancies worldwide. We aimed to identify novel prognostic markers by applying mass spectrometry (MS)‐based proteomic analysis to formalin‐fixed paraffin‐embedded (FFPE) tissues. Resectable, node positive pancreatic ductal adenocarcinoma (PDAC) with poor ( n = 4) and better ( n = 4) outcomes, based on survival duration, with essentially the same clinicopathological backgrounds, and noncancerous pancreatic ducts ( n = 5) were analyzed. Cancerous and noncancerous cells collected from FFPE tissue sections by laser microdissection (LMD) were processed for liquid chromatography (LC)‐tandem MS (MS/MS). Candidate proteins were identified by semiquantitative comparison and then analyzed quantitatively using selected reaction monitoring (SRM)‐based MS. To confirm the associations between candidate proteins and outcomes, we immunohistochemically analyzed a cohort of 87 cases. In result, totally 1,229 proteins were identified and 170 were selected as candidate proteins for SRM‐based targeted proteomics. Fourteen proteins overexpressed in cancerous as compared to noncancerous tissue showed different expressions in the poor and better outcome groups. Among these proteins, we found that three novel proteins ECH1, OLFM4 and STML2 were overexpressed in poor group than in better group, and that one known protein GTR1 was expressed reciprocally. Kaplan–Meier analysis showed high expressions of all four proteins to correlate with significantly worse overall survival ( p < 0.05). In conclusion, we identified four proteins as candidates of prognostic marker of PDAC. The combination of shotgun proteomics verified by SRM and validated by immunohistochemistry resulted in the prognostic marker discovery that will contribute the understanding of PDAC biology and therapeutic development.